The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
about
Pathophysiology of the peritoneal membrane during peritoneal dialysis: the role of hyaluronanBiocompatible dialysis fluids for peritoneal dialysisRegulation of synthesis and roles of hyaluronan in peritoneal dialysisEffect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-AnalysisMesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal DialysisPreservation of residual kidney function in hemodialysis patients: reviving an old concept.Analysis of protein glycation products by MALDI-TOF/MS.An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006.Tissue-advanced glycation end product concentration in dialysis patients.Outcomes of peritoneal dialysis patients and switching to hemodialysis: a competing risks analysisRationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal functionInfusion fluids contain harmful glucose degradation products.Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy.Increased peritoneal permeability at peritoneal dialysis initiation is a potential cardiovascular risk in patients using biocompatible peritoneal dialysis solutionEffect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials.Comparative outcomes between continuous ambulatory and automated peritoneal dialysis: a narrative review.High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients.Peritoneal Dialysis Drop-out: Causes and Prevention StrategiesImpact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ TrialMonitoring of the peritoneal membrane.The Effect of Neutral Peritoneal Dialysis Solution with Low Glucose-Degradation-Product on the Fluid Status and Body Composition--A Randomized Control Trial.Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.The transport barrier in intraperitoneal therapy.Effect of aldosterone on epithelial-to-mesenchymal transition of human peritoneal mesothelial cells.Encapsulating peritoneal sclerosis.Protecting the endothelium: a new focus for management of chronic kidney disease.A new neutral-pH low-GDP peritoneal dialysis fluid.The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.Balance about balANZ.Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.Trials (and tribulations) of biocompatible peritoneal dialysis fluidsA study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation productsEffect of the dialysis fluid buffer on peritoneal membrane function in childrenThe Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis.Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.The effect of low-GDP solution on ultrafiltration and solute transport in continuous ambulatory peritoneal dialysis patientsSelection of modalities, prescription, and technical issues in children on peritoneal dialysis.Aspects of immune dysfunction in end-stage renal disease
P2860
Q21296812-B75653BF-B1C6-49FF-AEC8-4FD6AC8F31A6Q24197836-C90B32E7-0FAB-4A63-9B35-E42130A45424Q26778414-E8C4720A-55F3-479B-90A8-9BC3B1F31881Q26852444-3FE89C34-EA8B-4C44-8DD0-8983BDA78970Q28390104-9E46CA44-F16E-4662-AFDE-5807038DD168Q30250300-3623BAE4-EEFF-441A-B659-412F893481E9Q33220105-62066DC0-F712-4D70-AA53-771307EE822CQ33509778-DB654E21-976C-4FE2-8B22-ACE95D106EEAQ33571288-48E123F6-73C8-4049-8D8D-3CEE999B2EF0Q33660321-EAC1FB40-6975-485A-BFA6-FC1F8C4D9949Q33693392-F67DE2D9-EEA0-4899-B2E4-F71E123BC858Q33899086-8A21567E-87A7-44E1-B2D8-AAF09CB631C0Q34208270-88515154-52D0-43DD-AFE1-56B22EFE4B0EQ34462389-0DDEEDA7-F100-43A8-A277-48D823C0A1F2Q34505567-3D956181-EEEF-452C-B89E-AEF7D2ED92DDQ34725102-A7AD8EEA-D272-466A-823F-83B34C55F2FBQ34989922-6FE51978-A33B-468B-BA13-A2548B73F935Q35106085-C3876965-22CD-4FCA-BBDD-41D86637E6EAQ35496077-94EBB1DC-F416-4595-8BCF-DE20BCFB6C11Q35524698-9DDC4741-DE2A-4D87-AB6B-91B00F51ED5CQ35524711-252F50F4-0C48-4159-B63D-7F0B1B870EB4Q35573609-93D95921-E248-408F-B494-1945FAE2BBCAQ35824659-8DD93FA1-8538-4D95-B9E9-162888CCF594Q35982392-DCBEF195-CC70-41F0-B4BD-D59553C03FDFQ36030299-C3D8E2D0-5EF0-43FD-926F-4960E003C57CQ36061883-9CB2A41F-559E-446A-8564-101C911460B4Q36164065-675E396D-BA26-49F6-9CC7-7094A4B7518BQ36379593-350ADFC1-0DD0-4CAF-820F-EA93658C208AQ36474168-AE2027A9-017B-4510-8D69-FE452ED68832Q36474236-EC6340AE-6B9A-41FB-9774-5FEC3CAB6981Q36474255-E8E2ED10-1766-4998-83DD-B93FD21A54B7Q36475639-870CBCA7-8D71-486F-83B2-E300B659E815Q36475670-5481948B-8740-44D9-91A3-C48B7FF430E3Q36475690-0D03589D-CDDC-4D30-A662-9ED01529C273Q36492525-99334288-5A74-4185-B085-DF5D9F887C6BQ36510083-70818D0D-49B3-4FE2-874E-E4FE179AAD8DQ36831478-190A525E-3D2C-4D8F-81EF-F10B83D19129Q37000687-91506220-8E2F-41A1-8C54-1425ADA4CFB0Q37181064-2547A5C7-49E9-4BE1-A91E-87CD1A6DB0AAQ37243143-05AB7800-71C4-4A3A-B28C-C02801ACF80B
P2860
The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The Euro-Balance Trial: the ef ...... e) on the peritoneal membrane.
@en
The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid
@nl
type
label
The Euro-Balance Trial: the ef ...... e) on the peritoneal membrane.
@en
The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid
@nl
prefLabel
The Euro-Balance Trial: the ef ...... e) on the peritoneal membrane.
@en
The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid
@nl
P2093
P1433
P1476
The Euro-Balance Trial: the ef ...... e) on the peritoneal membrane.
@en
P2093
Cristina Lage
Euro Balance Trial Group
John D Williams
Jutta Passlick-Deetjen
Kathrine J Craig
Monika Pischetsrieder
Nicholas Topley
Ruth K Mackenzie
P304
P356
10.1111/J.1523-1755.2004.00747.X
P407
P577
2004-07-01T00:00:00Z
P5875
P6179
1021315447